[Application of patient-reported-outcome in myelodysplastic syndromes].
作者信息
Liu L L, Xiao Z J
机构信息
State Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Diseases, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin 300020, China.
出版信息
Zhonghua Xue Ye Xue Za Zhi. 2022 Aug 14;43(8):700-704. doi: 10.3760/cma.j.issn.0253-2727.2022.08.019.
Abstract
摘要
相似文献
1
[Application of patient-reported-outcome in myelodysplastic syndromes].[患者报告结局在骨髓增生异常综合征中的应用]
Zhonghua Xue Ye Xue Za Zhi. 2022 Aug 14;43(8):700-704. doi: 10.3760/cma.j.issn.0253-2727.2022.08.019.
2
Patient-Reported Outcomes in Myelodysplastic Syndromes: the Move from Life Span to Health Span.骨髓增生异常综合征的患者报告结局：从生存时间到健康时间的转变。
Curr Hematol Malig Rep. 2020 Apr;15(2):149-154. doi: 10.1007/s11899-020-00562-9.
3
Patient-reported outcome measures in studies of myelodysplastic syndromes and acute myeloid leukemia: Literature review and landscape analysis.骨髓增生异常综合征和急性髓系白血病研究中的患者报告结局测量：文献回顾和全景分析。
Eur J Haematol. 2020 May;104(5):476-487. doi: 10.1111/ejh.13389. Epub 2020 Mar 3.
4
Patient-reported outcomes enhance the survival prediction of traditional disease risk classifications: An international study in patients with myelodysplastic syndromes.患者报告结局增强了传统疾病风险分类对生存预测的作用：一项国际研究纳入了骨髓增生异常综合征患者。
Cancer. 2018 Mar 15;124(6):1251-1259. doi: 10.1002/cncr.31193. Epub 2017 Dec 12.
5
Patient-Reported Outcomes in Myelodysplastic Syndromes and MDS/MPN Overlap Syndromes: Stepping Onto the Stage with Changing Times.骨髓增生异常综合征和骨髓增生异常综合征/骨髓增殖性肿瘤重叠综合征患者报告的结局：与时俱进登上舞台。
Curr Hematol Malig Rep. 2017 Oct;12(5):455-460. doi: 10.1007/s11899-017-0406-x.
6
Development of a core outcome set for myelodysplastic syndromes - a Delphi study from the EUMDS Registry Group.制定骨髓增生异常综合征核心结局集 - 来自 EUMDS 登记组的 Delphi 研究。
Br J Haematol. 2020 Nov;191(3):405-417. doi: 10.1111/bjh.16654. Epub 2020 May 14.
7
[Treatment of myelodysplastic syndromes].[骨髓增生异常综合征的治疗]
Pol Arch Med Wewn. 2001;105 Suppl:403-5.
8
[Management of myelodysplastic syndromes].[骨髓增生异常综合征的管理]
Bull Cancer. 2015 Nov;102(11):946-57. doi: 10.1016/j.bulcan.2015.07.007. Epub 2015 Sep 26.
9
Consensus statement on iron overload in myelodysplastic syndromes.骨髓增生异常综合征铁过载的共识声明。
Am J Hematol. 2008 Nov;83(11):858-61. doi: 10.1002/ajh.21269.
10
Stem cell transplants for myelodysplastic syndromes: refining the outcome predictions.骨髓增生异常综合征的干细胞移植：完善预后预测
Haematologica. 2014 Oct;99(10):1536-7. doi: 10.3324/haematol.2014.113555.
本文引用的文献
1
Biologic Assignment Trial of Reduced-Intensity Hematopoietic Cell Transplantation Based on Donor Availability in Patients 50-75 Years of Age With Advanced Myelodysplastic Syndrome.基于供者可用性的 50-75 岁中高危骨髓增生异常综合征患者减低强度异基因造血干细胞移植的生物学分配试验
J Clin Oncol. 2021 Oct 20;39(30):3328-3339. doi: 10.1200/JCO.20.03380. Epub 2021 Jun 9.
2
Targeting health-related quality of life in patients with myelodysplastic syndromes - Current knowledge and lessons to be learned.针对骨髓增生异常综合征患者的健康相关生活质量 - 当前的认识和有待吸取的教训。
Blood Rev. 2021 Nov;50:100851. doi: 10.1016/j.blre.2021.100851. Epub 2021 May 14.
3
Current Therapy of the Patients with MDS: Walking towards Personalized Therapy.骨髓增生异常综合征患者的当前治疗：迈向个性化治疗
J Clin Med. 2021 May 13;10(10):2107. doi: 10.3390/jcm10102107.
4
Phase III, Randomized, Placebo-Controlled Trial of CC-486 (Oral Azacitidine) in Patients With Lower-Risk Myelodysplastic Syndromes.III 期、随机、安慰剂对照临床试验：CC-486（口服阿扎胞苷）治疗低危骨髓增生异常综合征患者。
J Clin Oncol. 2021 May 1;39(13):1426-1436. doi: 10.1200/JCO.20.02619. Epub 2021 Mar 25.
5
[Clinical Efficacy of the MDS Patients Treated by Allo-HSCT].[异基因造血干细胞移植治疗骨髓增生异常综合征患者的临床疗效]
Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2021 Feb;29(1):172-180. doi: 10.19746/j.cnki.issn.1009-2137.2021.01.027.
6
Current and emerging strategies for management of myelodysplastic syndromes.当前和新兴的骨髓增生异常综合征治疗策略。
Blood Rev. 2021 Jul;48:100791. doi: 10.1016/j.blre.2020.100791. Epub 2020 Dec 27.
7
Hematological Malignancy Specific Patient-Reported Outcome Measure (HM-PRO): Construct Validity Study.血液系统恶性肿瘤特异性患者报告结局量表（HM-PRO）：结构效度研究
Front Pharmacol. 2020 Sep 8;11:1308. doi: 10.3389/fphar.2020.01308. eCollection 2020.
8
Content validity of patient-reported outcomes for use in lower-risk myelodysplastic syndromes.用于低风险骨髓增生异常综合征的患者报告结局的内容效度。
J Patient Rep Outcomes. 2020 Aug 26;4(1):69. doi: 10.1186/s41687-020-00235-4.
9
Development of a Novel Hematological Malignancy Specific Patient-Reported Outcome Measure (HM-PRO): Content Validity.一种新型血液系统恶性肿瘤特异性患者报告结局量表（HM-PRO）的开发：内容效度
Front Pharmacol. 2020 Mar 5;11:209. doi: 10.3389/fphar.2020.00209. eCollection 2020.
10
Patient-Reported Outcomes in Myelodysplastic Syndromes: the Move from Life Span to Health Span.骨髓增生异常综合征的患者报告结局：从生存时间到健康时间的转变。
Curr Hematol Malig Rep. 2020 Apr;15(2):149-154. doi: 10.1007/s11899-020-00562-9.
Zotero 插件